急性呼吸窘迫综合征随机对照试验中的衰弱参与者
本研究对2006年至2019年间发表的五项ARDS Network和PETAL Network试验进行二次分析,基于住院前需要日常帮助将3630例ARDS参与者分为衰弱与非衰弱。衰弱参与者701例(19.3%),其比例随时间增加(P=0.001),但死亡率保持稳定(P=0.403)且高达39.4%。衰弱独立关联90天死亡率(OR 1.62,95%CI 1.34-1.96,P<0.001),衰弱者无呼吸机天数更少且更可能遗留残疾。作者认为试验设计应考虑日益增加的衰弱脆弱群体。
要点
- 在ARDS试验中,衰弱参与者占19.3%(701/3630),比例随时间增加(P=0.001)。
- 衰弱参与者死亡率保持稳定(P=0.403)且高达39.4%。
- 衰弱独立关联90天死亡率(OR 1.62,95%CI 1.34-1.96,P<0.001)。
- 60.6%的衰弱参与者年龄小于65岁。
- 衰弱者无呼吸机天数更少,且更可能遗留残疾。
适用人群与场景
- 五项ARDS Network和PETAL Network随机对照试验的参与者,共3630例ARDS患者,试验发表于2006年至2019年。
- 基于住院前需要日常帮助分为衰弱与非衰弱。
诊断标准与关键阈值
- 衰弱定义:住院前需要日常帮助。
研究设计与关键结果
- 研究类型:对五项ARDS Network和PETAL Network随机对照试验的二次分析。
- 样本量:3630例ARDS参与者,其中衰弱701例(19.3%)。
- 衰弱参与者比例随时间增加(P=0.001)。
- 衰弱参与者死亡率保持稳定(P=0.403),高达39.4%。
- 60.6%的衰弱参与者年龄小于65岁。
- 衰弱独立关联90天死亡率(OR 1.62,95%CI 1.34-1.96,P<0.001)。
- 衰弱者无呼吸机天数更少,且更可能遗留残疾。
证据类型、等级与局限
- 证据类型:对随机对照试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,试验设计应考虑日益增加的衰弱参与者这一脆弱群体。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Purpose: Observational studies showed that frailty is common in the intensive care unit and associated with poor outcomes. However, relevant data from interventional trials are scarce, and it is unknown whether outcomes improved over time. We endeavored to estimate temporal trends of representation and outcomes of frail participants in randomized controlled trials of acute respiratory distress syndrome (ARDS). Methods: We performed a secondary analysis of five ARDS Network and PETAL Network trials published between 2006 and 2019. Based on requirement for everyday assistance prior to hospitalization, we categorized participants into frail versus nonfrail. Results : Out of 3,630 participants with ARDS, 701 (19.3%) were frail. Representation of frail participants increased over time ( P = 0.001), while mortality remained stable ( P = 0.403) and as high as 39.4%. A total of 60.6% of frail participants were younger than 65 years old. Frailty was independently associated with 90-day mortality (odds ratio 1.62, 95% confidence interval 1.34-1.96, P < 0.001). Frail had fewer ventilator-free days and were more likely to have subsequent disability than nonfrail participants. Conclusion: In trials of ARDS, representation of frail participants increased, while their mortality did not improve over time. The ever-increasing vulnerable group of frail participants should be taken into consideration in the design of trials.
参考来源
- Ntaidou TK, Giannakoulis VG, Papoutsi E, et al. FRAIL PARTICIPANTS IN RANDOMIZED CONTROLLED TRIALS OF ACUTE RESPIRATORY DISTRESS SYNDROME. Shock. 2025. PMID: 39993922. doi:10.1097/SHK.0000000000002517
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。